<DOC>
	<DOC>NCT00174733</DOC>
	<brief_summary>To investigate the efficacy of ciclesonide MDI either as once daily or a twice daily regimen in patients with mild to moderate asthma, who have previously been treated with an inhaled corticosteroid.</brief_summary>
	<brief_title>Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>Males or females 12 years or older History of persistent bronchial asthma for at least 6 months Documented use of an inhaled steroid or a combination of an inhaled steroid/longacting beta 2 agonist for at least 1 month before screening At screening, FEV1 of 60 to 90% predicted or 70 to 95% predicted for either ICS or ICS/LABA use respectively.Reversibility of FEV1 by at least 12% and 200 ml postbronchodilator Be able to use oral inhalers Nonsmokers History of lifethreatening asthma Other pulmonary diseases; URI within 4 weeks before screening Use of systemic steroids within 1 month before screening or more than 3 times in previous 6 months Betaadrenergic blocking agent use More than 2 inpatient hospitalizations or ER visits due to asthma exacerbations in the prior year before screening Pregnant or breastfeeding females Females of childbearing potential not using adequate means of birth control Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease Abnormal clinical laboratory parameters that would limit participation in the study or interfere with interpretation of study results History of drug or alcohol abuse Treatment with any investigational product within 30 days prior to study entry</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Glucocorticosteroid. Bronchospasm</keyword>
</DOC>